Johnson & Johnson, a pharmaceutical, and medical technologies corporation, agreed to acquire Proteologix, a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850m. “Atopic dermatitis is the most common inflammatory skin disease, impacting more than 100 million adults worldwide. About 70% of patients using existing standard of care therapies do not reach remission1. Current advanced therapies for AD either target a single pathway and have limited efficacy or are more broadly immunosuppressive, resulting in significant safety concerns. We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease driving pathways that are mediating the skin inflammation in heterogenous subpopulations of AD patients,” David Lee, Johnson & Johnson Global Immunology Therapeutic Area Head.